Home › Research › Risk factors
New evidence on the management of Lewy body dementia
Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, Allan LM, Thomas AJ et al.. The Lancet. Neurology, 2019-09-10
Topic: Risk, prevention and care in population studies
Plain-language summary
Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
What this study adds
Evidence grade: High
This is a pooled review. This review states that clinical trials and meta-analyses now provide an evidence base for treating cognitive, neuropsychiatric, and motor symptoms in Lewy body dementia, but that treatments can improve one symptom while worsening another and evidence gaps remain. It is about managing symptoms of Lewy body dementia, not curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Taylor, J. P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., et al. (2020). New evidence on the management of Lewy body dementia. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(19)30153-x
Vancouver
Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. The Lancet. Neurology. 2020. doi:10.1016/s1474-4422(19)30153-x. PMID: 31519472.
BibTeX
@article{taylor2020-31519472,
author = {Taylor, J. P. and McKeith, I. G. and Burn, D. J. and Boeve, B. F. and Weintraub, D. and Bamford, C. and Allan, L. M. and Thomas, A. J. and others},
title = {{New evidence on the management of Lewy body dementia}},
journal = {The Lancet. Neurology},
year = {2020},
doi = {10.1016/s1474-4422(19)30153-x},
pmid = {31519472},
url = {https://doi.org/10.1016/s1474-4422(19)30153-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Treatments can address one symptom but worsen another, which makes disease management difficult.
- Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish.
- Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia.
- Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia.
- However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
Why it matters
This review states that clinical trials and meta-analyses now provide an evidence base for treating cognitive, neuropsychiatric, and motor symptoms in Lewy body dementia, but that treatments can improve one symptom while worsening another and evidence gaps remain. It is about managing symptoms of Lewy body dementia, not curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Study designmeta-analysis
- Evidence strengthHigh
How this study scored 71/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 6 / 7 | Cited 342 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 42.8 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 4 / 6 | Cited 17.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 24 other studies in this library |
| Still being cited | 3 / 4 | Cited 161 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author John Tiernan O'Brien: h-index 140 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31519472) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/s1474-4422(19)30153-x
- PubMed: 31519472
- Original source →
- Free full text: Open Research Exeter (University of Exeter) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Risk factors from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.